Oncology Pricing & Reimbursement Analysis

Service Features

• Nearly 5000+ approved and R&D drugs for oncology and supportive care within France, the United Kingdom, and the United States
• Clinical information, updated daily
• Detailed coverage of 40 criteria—including cost per QALY; special authority restrictions; hospital status; average monthly cost; price data; clinical trial design, endpoints and results; black box warnings; patent expiration; and approval information (including impending PDUFA dates, expected upcoming filings, new indications, and orphan drug designations)
• Ability to search and sort by drug, company, cancer area, drug class, insurance plan, and clinical endpoint
• Fully customizable: choose precisely what you want to see
• Downloadable to Microsoft Excel

• Tracks all major events in oncology, including regulatory submissions, price changes, major conferences, clinical data, and M&A related to this sector Cancer area, drug class, and regulatory profiles
• Exclusive information for all significant cancer areas (e.g.: breast cancer, acute myeloid leukaemia, and supportive care)—including standard of care, major new drug approvals, market data, and significant

• Exclusive information for all significant cancer areas (e.g.: breast cancer, acute myeloid leukaemia, and supportive care)—including standard of care, major new drug approvals, market data, and significant R&D trends
• Overview of all drug classes related to the cancer including older areas (e.g.: plant alkaloids), newer areas (e.g.: TK inhibitors, HDAC inhibitors), and non-approved classes (e.g.: HSP90 inhibitors)
• Overview of all the major oncology-related regulatory mechanisms and pricing developments in the United Kingdom, France, and the United States